Abstract 983P
Background
The HIMALAYA trial demonstrated that the efficacy of durvalumab (an PD-L1 inhibitor) is comparable to that of sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC), and its safety profile is more acceptable. The FOHAIC-1 study indicated that hepatic arterial infusion chemotherapy (HAIC) achieves better survival than sorafenib in advanced HCC with intrahepatic high-risk factors (i.e., Vp4 portal vein tumor thrombosis [PVTT]). This study aimed to evaluate the safety and efficacy of durvalumab plus HAIC as first-line therapy in pts with HCC with Vp3/4 PVTT.
Methods
The DurHope study was a single-arm, phase 2 trial. Eligible pts had HCC with Vp3/4 PVTT with no previous systemic treatment. Pts received HAIC of FOLFOX regimens (oxaliplatin 130 mg/m2, leucovorin 200 mg/m2, fluorouracil 400 mg/m2, and fluorouracil 2,400 mg/m2) on day 1–3 plus durvalumab (1120 mg) intravenously on day 7 (±2) of each 21-day cycle for 8 cycles, followed by maintenance with durvalumab (1500 mg) every 28 days until disease progression, unacceptable toxicity, or death. The primary endpoint was 1-year overall survival (OS) rate. Secondary endpoints were progression-free survival (PFS), objective response rate (ORR) per RECIST v1.1, and safety.
Results
In this interim analysis, as of March 20, 2023, 19 pts who received at least one cycle of durvalumab and HAIC were included. The ORR was 47.4% (9/19) with 1 complete response and 8 partial response. The median time to response was 1.3 months (95% CI, 1.3–2.7), and the median duration of response was 5.4 months (95% CI, 3.7–5.8). The most common treatment-emergent adverse events (TEAEs) were hypoalbuminemia (18 [94.7%]), anaemia (17 [89.5%]), and neutropenia (16 [84.2%]). Grade 3/4 TEAEs occurred in 13 pts (68.4%). Two pts (10.5%) experienced grade 4 upper gastrointestinal bleeding.
Conclusions
Combination treatment with durvalumab and HAIC showed promising antitumor activity with ORR of 47.4% in HCC with Vp3/4 PVTT. Prophylactic gastrointestinal endoscope might be necessary to decrease the risk of gastrointestinal bleeding in such pts. Enrollment is ongoing and longer follow-up is needed to evaluate the survival data.
Clinical trial identification
NCT04945720.
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18